Zackariah Clement1, James Kollias1,2, Janne Bingham1,2, Robert Whitfield1,2, Melissa Bochner1,2. 1. Breast and Endocrine Surgery Unit, Royal Adelaide Hospital, Adelaide, Australia. 2. Senior Clinical Lecturer, Department of Surgery, Adelaide Medical School, University of Adelaide, Adelaide, Australia.
Abstract
BACKGROUND: The risk of hormone positive breast cancer extends beyond 5 years. Extended duration of tamoxifen to 10 years has been shown to improve overall survival (OS) and disease-free survival (DFS). In post-menopausal women aromatase inhibitor (AI) is the gold standard for adjuvant endocrine therapy. Several randomized controlled trials (RCTs) showed benefit with extending the duration of AIs in post-menopausal women. However, the duration and the overall benefit is still controversial. METHODS: Eligible 8 RCTs comprising of 17,190 participants were included in this meta-analysis. RESULTS: Extending the duration of AI did not show any statistically significant advantage in OS with OR of 1.033 (95% CI: 0.925-1.154, P=0.56), DFS OR of 1.049 (95% CI: 0.930-1.185, P=0.435), recurrence-free survival (RFS) OR of 1.063 (95% CI: 0.952-1.187, P=0.276), and contralateral breast cancer (CBC) OR of 1.094 (95% CI: 0.920-1.301, P=0.311). Higher rates of side-effects of arthralgia, myalgia, hot flushes and bone toxicity was seen among the extended AI group. CONCLUSIONS: Based on this meta-analysis and current literature review, extended use of AI after 5 years of endocrine therapy should be used in selected women with high risk tumour factors. Molecular markers and genomic profiling may assist in identifying the high-risk patients. It is important to consider quality of life and patient satisfaction when considering extending the duration of AI.
BACKGROUND: The risk of hormone positive breast cancer extends beyond 5 years. Extended duration of tamoxifen to 10 years has been shown to improve overall survival (OS) and disease-free survival (DFS). In post-menopausal women aromatase inhibitor (AI) is the gold standard for adjuvant endocrine therapy. Several randomized controlled trials (RCTs) showed benefit with extending the duration of AIs in post-menopausal women. However, the duration and the overall benefit is still controversial. METHODS: Eligible 8 RCTs comprising of 17,190 participants were included in this meta-analysis. RESULTS: Extending the duration of AI did not show any statistically significant advantage in OS with OR of 1.033 (95% CI: 0.925-1.154, P=0.56), DFS OR of 1.049 (95% CI: 0.930-1.185, P=0.435), recurrence-free survival (RFS) OR of 1.063 (95% CI: 0.952-1.187, P=0.276), and contralateral breast cancer (CBC) OR of 1.094 (95% CI: 0.920-1.301, P=0.311). Higher rates of side-effects of arthralgia, myalgia, hot flushes and bone toxicity was seen among the extended AI group. CONCLUSIONS: Based on this meta-analysis and current literature review, extended use of AI after 5 years of endocrine therapy should be used in selected women with high risk tumour factors. Molecular markers and genomic profiling may assist in identifying the high-risk patients. It is important to consider quality of life and patient satisfaction when considering extending the duration of AI.
Authors: Fausto Petrelli; Andrea Coinu; Mary Cabiddu; Mara Ghilardi; Veronica Lonati; Sandro Barni Journal: Breast Cancer Res Treat Date: 2013-07-17 Impact factor: 4.872
Authors: Hadar Goldvaser; Tristan A Barnes; Boštjan Šeruga; David W Cescon; Alberto Ocaña; Domen Ribnikar; Eitan Amir Journal: J Natl Cancer Inst Date: 2018-01-01 Impact factor: 13.506
Authors: Martin Filipits; Torsten O Nielsen; Margaretha Rudas; Richard Greil; Herbert Stöger; Raimund Jakesz; Zsuzsanna Bago-Horvath; Otto Dietze; Peter Regitnig; Christine Gruber-Rossipal; Elisabeth Müller-Holzner; Christian F Singer; Brigitte Mlineritsch; Peter Dubsky; Thomas Bauernhofer; Michael Hubalek; Michael Knauer; Harald Trapl; Christian Fesl; Carl Schaper; Sean Ferree; Shuzhen Liu; J Wayne Cowens; Michael Gnant Journal: Clin Cancer Res Date: 2014-02-11 Impact factor: 12.531
Authors: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater Journal: J Clin Oncol Date: 2007-04-23 Impact factor: 44.544
Authors: Raimund Jakesz; Richard Greil; Michael Gnant; Marianne Schmid; Werner Kwasny; Ernst Kubista; Brigitte Mlineritsch; Christoph Tausch; Michael Stierer; Friedrich Hofbauer; Karl Renner; Christian Dadak; Ernst Rücklinger; Hellmut Samonigg Journal: J Natl Cancer Inst Date: 2007-12-11 Impact factor: 13.506
Authors: Paul E Goss; James N Ingle; Kathleen I Pritchard; Nicholas J Robert; Hyman Muss; Julie Gralow; Karen Gelmon; Tim Whelan; Kathrin Strasser-Weippl; Sheldon Rubin; Keren Sturtz; Antonio C Wolff; Eric Winer; Clifford Hudis; Alison Stopeck; J Thaddeus Beck; Judith S Kaur; Kate Whelan; Dongsheng Tu; Wendy R Parulekar Journal: N Engl J Med Date: 2016-06-05 Impact factor: 91.245
Authors: Jacquie H Chirgwin; Anita Giobbie-Hurder; Alan S Coates; Karen N Price; Bent Ejlertsen; Marc Debled; Richard D Gelber; Aron Goldhirsch; Ian Smith; Manuela Rabaglio; John F Forbes; Patrick Neven; István Láng; Marco Colleoni; Beat Thürlimann Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544
Authors: C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto Journal: Lancet Date: 2011-07-28 Impact factor: 79.321
Authors: Leonor Vasconcelos de Matos; Leonor Fernandes; Maria Teresa Neves; Fátima Alves; Mafalda Baleiras; André Ferreira; Pedro Giesteira Cotovio; Tiago Dias Domingues; Mariana Malheiro; Ana Plácido; Maria Helena Miranda; Ana Martins Journal: Curr Oncol Date: 2021-02-26 Impact factor: 3.677
Authors: Gábor Rubovszky; Judit Kocsis; Katalin Boér; Nataliya Chilingirova; Magdolna Dank; Zsuzsanna Kahán; Dilyara Kaidarova; Erika Kövér; Bibiana Vertáková Krakovská; Károly Máhr; Bela Mriňáková; Béla Pikó; Ivana Božović-Spasojević; Zsolt Horváth Journal: Pathol Oncol Res Date: 2022-07-11 Impact factor: 2.874